Page last updated: 2024-10-30

losartan and Deafness, Transitory

losartan has been researched along with Deafness, Transitory in 2 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Research Excerpts

ExcerptRelevanceReference
"Hearing loss is one of the most common symptoms of neurofibromatosis type 2 (NF2) caused by vestibular schwannomas (VSs)."5.62Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models. ( Brown, A; Chen, J; Datta, M; Early, S; Gao, X; Ho, WW; Jain, RK; Landegger, LD; Lee, GY; Muzikansky, A; Plotkin, SR; Ren, J; Sagers, JE; Stankovic, KM; Stemmer-Rachamimov, A; Sun, Y; Vasilijic, S; Wu, L; Xu, L; Yin, Z; Zhang, L; Zhang, N; Zhang, Y; Zhou, W, 2021)
"Hearing loss is one of the most common symptoms of neurofibromatosis type 2 (NF2) caused by vestibular schwannomas (VSs)."1.62Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models. ( Brown, A; Chen, J; Datta, M; Early, S; Gao, X; Ho, WW; Jain, RK; Landegger, LD; Lee, GY; Muzikansky, A; Plotkin, SR; Ren, J; Sagers, JE; Stankovic, KM; Stemmer-Rachamimov, A; Sun, Y; Vasilijic, S; Wu, L; Xu, L; Yin, Z; Zhang, L; Zhang, N; Zhang, Y; Zhou, W, 2021)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Wu, L1
Vasilijic, S1
Sun, Y1
Chen, J1
Landegger, LD1
Zhang, Y1
Zhou, W1
Ren, J1
Early, S1
Yin, Z1
Ho, WW1
Zhang, N1
Gao, X1
Lee, GY1
Datta, M1
Sagers, JE1
Brown, A1
Muzikansky, A1
Stemmer-Rachamimov, A1
Zhang, L1
Plotkin, SR1
Jain, RK1
Stankovic, KM1
Xu, L1
Meyer zum Gottesberge, AM1
Massing, T1
Sasse, A1
Palma, S1
Hansen, S1

Other Studies

2 other studies available for losartan and Deafness, Transitory

ArticleYear
Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models.
    Science translational medicine, 2021, 07-14, Volume: 13, Issue:602

    Topics: Animals; Hearing Loss; Humans; Losartan; Mice; Neurilemmoma; Neurofibromatosis 2; Prospective Studie

2021
Zucker diabetic fatty rats, a model for type 2 diabetes, develop an inner ear dysfunction that can be attenuated by losartan treatment.
    Cell and tissue research, 2015, Volume: 362, Issue:2

    Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hearing Loss; Hyperglycemia; La

2015